Tirzepatide Research: The SURPASS and SURMOUNT Trial Record

The short version

The tirzepatide research record spans three categories: (1) mechanistic work that explains how the molecule behaves at the GIP and GLP-1 receptors and what it does to the pancreas's ability to secrete insulin and respond to blood sugar; (2) the large phase 3 trials in type 2 diabetes (SURPASS) and obesity (SURMOUNT) that generated the efficacy and safety data supporting FDA approval; and (3) emerging data from the expanded indication programme — sleep apnea, heart failure, and liver disease.

The two headline numbers are a disposition index advantage of 0.84 over the leading comparator in a dedicated mechanistic clamp study (the clearest evidence that the dual mechanism works as intended), and a -20.9% mean body weight reduction at 72 weeks in the pivotal obesity trial ^[4][8]. The head-to-head obesity trial confirmed that -20.2% versus -13.7% for the comparator — a statistically significant advantage ^[5].

This page organises the key studies in that order: mechanism first, then the efficacy programmes.

Mechanism and receptor pharmacology

Discovery and Phase 1 (Coskun et al., Mol Metab, 2018): The founding paper for LY3298176 established in vitro activation of both GIP and GLP-1 receptors, superior body weight and food intake reduction versus a selective GLP-1 receptor agonist in mice, and Phase 1 data in 142 human subjects confirming once-weekly PK support and reductions in fasting glucose and body weight ^[1].

Receptor pharmacology (Willard et al., JCI Insight, 2020): Characterised tirzepatide as an imbalanced GIPR-preferring dual agonist and a biased GLP-1 receptor agonist (cAMP-over-beta-arrestin). In primary islets, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide — a mechanism that may explain enhanced insulin secretion ^[2].

Disposition index (Heise et al., Lancet Diabetes Endocrinol, 2022, n=117): The pivotal mechanistic trial. Clamp disposition index ETD versus placebo: 1.92 (95% CI 1.59–2.24; p<0.0001). ETD versus semaglutide: 0.84 (95% CI 0.46–1.21; p<0.0001). Greater improvements in insulin secretion rate and M-value (insulin sensitivity) than semaglutide, with larger reductions in meal-test insulin and glucagon excursions ^[8].

Gastric emptying (Urva et al., Diabetes Obes Metab, 2020): Tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. The effect attenuates with continued dosing ^[21].

GIPR/GLP-1R dual agonist physiology (Campbell et al., Cell Metab, 2023): A comprehensive review of the chemistry, physiology, and clinical applications of the dual incretin mechanism, placing tirzepatide in the broader landscape of incretin biology ^[35].

Phase 3 efficacy: the SURPASS programme (type 2 diabetes)

SURPASS-2 (Frias JP et al., N Engl J Med, 2021, n=1879, 40 weeks): The pivotal head-to-head trial. Tirzepatide 5/10/15 mg reduced HbA1c by 2.01/2.24/2.30 percentage points versus 1.86 percentage points with semaglutide 1 mg — non-inferior and superior at all three doses. Body weight reductions were 1.9, 3.6, and 5.5 kg greater than semaglutide. The most common adverse events were gastrointestinal and mostly mild to moderate ^[3].

Beta-cell function — SURPASS-1 monotherapy (Thomas MK et al., J Endocr Soc, 2023): A dedicated substudy of SURPASS-1 reported improved beta-cell function and insulin sensitivity markers under monotherapy at all three doses versus placebo ^[10].

Japanese population — SURPASS J-mono (Hamamoto Y et al., Diabetes Ther, 2025, n=636): All three tirzepatide doses significantly improved HOMA2-%S (insulin sensitivity) and HOMA2-%B (beta-cell function) versus dulaglutide at 52 weeks, with significant reductions in fasting insulin (ETDs -22.6% to -31.0%) and C-peptide (-14.2% to -20.7%) ^[19].

Early response predictors (Giorgino F et al., Diabetes Care, 2025): A post-hoc pooled analysis of the SURPASS trials found that early glycaemic response (≥20% fasting glucose reduction at week 4) or early weight response (≥5% at week 8) predicted better long-term HbA1c and metabolic outcomes. Non-early responders still achieved clinically meaningful reductions at all doses ^[11].

Older adults (Rasouli N et al., Diabetes Ther, 2025): A post-hoc SURPASS analysis in older adults found hypoglycaemia incidence was consistent regardless of background insulin or sulfonylurea use — relevant to the safety framing for comorbid populations ^[25].

Tirzepatide vs semaglutide — the key comparison: SURPASS-2 showed superiority on HbA1c reduction and greater body weight reduction at all doses versus semaglutide 1 mg ^[3].

Tirzepatide dosage

In the SURPASS and SURMOUNT phase 3 programmes, tirzepatide dosage followed a stepwise titration schedule: 2.5 mg once weekly for the first four weeks, then increasing by 2.5 mg every four weeks to the maintenance dose. The three maintenance doses studied were 5, 10, and 15 mg once weekly ^[1][3][4].

The FDA label specifies the same stepwise titration schedule for the approved indications. Labeled dose ranges are documented in the prescribing information as specific to the indicated population ^[12].

Tirzepatide dose and exposure-response

Dose-response was clear across both programmes: higher doses produced larger HbA1c reductions (2.01% at 5 mg, 2.30% at 15 mg, SURPASS-2) and larger body weight reductions (-15.0% at 5 mg, -20.9% at 15 mg, SURMOUNT-1) ^[3][4]. This tirzepatide dose escalation approach is designed to manage gastrointestinal tolerability while allowing maximum therapeutic effect at steady state.

Phase 3 efficacy: the SURMOUNT programme (obesity)

SURMOUNT-1 (Jastreboff AM et al., N Engl J Med, 2022, n=2539, 72 weeks): 2539 adults with obesity or overweight plus a weight-related complication, without diabetes. Mean weight change at week 72: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. The most common adverse events were gastrointestinal and mostly mild to moderate, occurring primarily during dose escalation ^[4].

Tirzepatide weight loss — the magnitude: At the 15 mg dose in SURMOUNT-1, 96% of participants achieved ≥5% weight reduction; 88% achieved ≥10%; 56% achieved ≥20%. These response rates were unprecedented in a phase 3 obesity trial ^[4].

SURMOUNT-5 (Aronne LJ et al., N Engl J Med, 2025, n=751, 72 weeks): Open-label head-to-head trial comparing the maximum tolerated dose of tirzepatide (10 or 15 mg) versus the maximum tolerated dose of the comparison drug (1.7 or 2.4 mg once weekly). Least-squares mean weight change: tirzepatide -20.2% versus comparison drug -13.7% (p<0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss ^[5].

SURMOUNT-4 — weight regain after discontinuation (Aronne LJ et al., JAMA, 2024, n=670): Participants who achieved weight loss on tirzepatide then randomised to placebo regained weight while those continuing on tirzepatide maintained and extended their weight loss, demonstrating the need for continued treatment to maintain the cardiometabolic benefit ^[29].

Beta-cell function post-hoc (Mari A et al., Diabetes Care, 2025): Post-hoc SURMOUNT-1 analysis in adults with prediabetes or normoglycaemia. At week 72, improvements in insulin sensitivity were mostly associated with weight reduction, while beta-cell function enhancement was partly weight-independent — evidence of a direct drug effect on pancreatic function ^[20].

Body composition (Look M et al., Diabetes Obes Metab, 2025): DXA substudy of SURMOUNT-1 found approximately 25% of weight lost was lean mass, 75% fat mass ^[26].

Tirzepatide reviews: cardiovascular and expanded indication data (2024–2025)

Real-world cardiovascular outcomes across 8 retrospective cohorts (N=118,252) found tirzepatide versus control associated with: ACS HR 0.74; HF HR 0.65; stroke HR 0.71; MACE HR 0.72; all-cause mortality HR 0.49 ^[36]. Versus the comparison drug specifically, tirzepatide showed lower stroke and MACE but similar ACS, HF, and all-cause mortality rates.

SURMOUNT-OSA (Malhotra A et al., N Engl J Med, 2024): Tirzepatide reduced the apnea-hypopnea index by 25 events per hour in adults with moderate-to-severe OSA not using CPAP, with 42% achieving OSA resolution ^[16].

SUMMIT (Packer M et al., N Engl J Med, 2025): Tirzepatide improved a composite of cardiovascular death or worsening heart failure events in adults with HFpEF and obesity ^[17].

SYNERGY-NASH (Loomba R et al., N Engl J Med, 2024): In adults with MASH and liver fibrosis, tirzepatide produced significant improvements in MASH resolution and fibrosis regression ^[18].